Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Alana on +44 1494 818 020 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Alana McKenna
Principal Account Manager
+44 1494 818 020

Thank you so much for your comprehensive efforts. I must admit it is a refreshing surprise to have such an informative response. I can assure you it is really appreciated.
Shan, 2013

Ark Therapeutics achieves milestone in PsiOxus partnership

5 January 2012 00:00 in Medical Company Product News

Ark Therapeutics has successfully met the first milestone in its manufacturing alliance with PsiOxus Therapeutics, as outlined in September 2011.

The company has been able to produce the ColoAd1 oncoloytic adenoviral product at its facility in Kuopio, Finland in a timely manner, allowing PsiOxus to initiate final pre-clinical toxicology studies of the compound.

Ark utilises its proprietary suspension-based single use process ATOSUS to achieve the necessary product quality and demonstrate the capability to exceed target process yields, which will aid its partner's plans to commence phase I testing in 2012.

This will help to bring a potentially promising new therapy option for colorectal cancer one step closer to market readiness.

Martyn Williams, chief executive officer of Ark, added: "This further validation for Ark's ATOSUS process as a platform for adenoviral manufacture is very helpful as we continue discussions with other potential partners."

This comes after Ark recently agreed to provide manufacturing services for the University of Glasgow in order to support a gene therapy programme.ADNFCR-8000103-ID-801256313-ADNFCR

Other news stories from 05/01/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd